Pharma Mar (PHMMF) Projected to Post Earnings on Wednesday

Pharma Mar (OTCMKTS:PHMMF) will likely be posting its resultson Wednesday, July 29th. Analysts expect Pharma Mar to announce earnings of $0.2027 per share and revenue of $51.0340 million for the quarter.

Pharma Mar Price Performance

Shares of PHMMF opened at $86.09 on Monday. The company has a debt-to-equity ratio of 0.14, a current ratio of 3.02 and a quick ratio of 2.44. Pharma Mar has a one year low of $77.41 and a one year high of $110.40. The business’s 50 day simple moving average is $91.98 and its 200-day simple moving average is $93.89.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on PHMMF shares. BTIG Research began coverage on Pharma Mar in a research report on Thursday, April 23rd. They issued a “buy” rating for the company. Chardan Capital upgraded Pharma Mar to a “strong-buy” rating in a report on Tuesday, June 9th. Finally, Zacks Research upgraded Pharma Mar to a “hold” rating in a report on Monday, June 15th. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy”.

Pharma Mar Company Profile

PharmaMar is a Spain-based biopharmaceutical company that specializes in the discovery and development of novel oncology therapies derived from marine organisms. Founded in 1986 as part of Grupo Zeltia, the company has pioneered the use of compounds extracted from deep-sea organisms to create synthetic analogs aimed at treating various forms of cancer. Its core expertise lies in marine biotechnology, medicinal chemistry and oncology-focused clinical development.

The company’s flagship product is Yondelis (trabectedin), an antitumor agent approved in the European Union for the treatment of soft tissue sarcoma and relapsed platinum-sensitive ovarian cancer.